Title |
Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models
|
---|---|
Published in |
Journal of Ovarian Research, November 2013
|
DOI | 10.1186/1757-2215-6-78 |
Pubmed ID | |
Authors |
Zaynab Al-Eisawi, Philip Beale, Charles Chan, Jun Q Yu, Fazlul Huq |
Abstract |
Ovarian cancer remains an on-going challenge mainly due to the development of drug resistance and also because the cancer is likely to have metastasized at the time of diagnosis. Currently, chemotherapy based on platinum drugs such as cisplatin is the primary treatment for the disease. Copper transporter 1 is involved in the transport of cisplatin into the cell, but is also down-regulated by the drug. Bortezomib, a proteasome inhibitor, has been reported to block this platinum-induced down-regulation of CTR1, so that in the presence of bortezomib, the cellular uptake of platinum drugs may be increased. Increased platinum accumulation may result in increased platinum - DNA binding so that the platinum drug in combination with bortezomib may produce enhanced cell kill. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 6% |
Luxembourg | 1 | 6% |
Unknown | 14 | 88% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Professor > Associate Professor | 3 | 19% |
Researcher | 3 | 19% |
Student > Ph. D. Student | 3 | 19% |
Unspecified | 1 | 6% |
Student > Doctoral Student | 1 | 6% |
Other | 2 | 13% |
Unknown | 3 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 4 | 25% |
Agricultural and Biological Sciences | 3 | 19% |
Medicine and Dentistry | 2 | 13% |
Unspecified | 1 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 6% |
Other | 1 | 6% |
Unknown | 4 | 25% |